Semaglutide for Alcoholism
(SEMA AUD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
Who Is on the Research Team?
Rajita Sinha
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
This trial is for adults who have both alcohol use disorder and obesity. People with other serious health problems or conditions that could interfere with the study may not be able to join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 1.0 mg or 2.0 mg of Semaglutide or placebo weekly to assess alcohol and food craving, stress, and alcohol use outcomes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Semaglutide
Trial Overview
The study compares two doses of semaglutide (1.0 mg and 2.0 mg) against a placebo to see if they help reduce alcohol cravings, stress, and drinking in people with both alcoholism and obesity.
How Is the Trial Designed?
3
Treatment groups
Active Control
Placebo Group
Semaglutide low dose of 1.0 mg administered weekly over the 20-weeks trial
Semaglutide high dose 2.0 mg administered weekly over the 20-weeks trial
Placebo saline pen administered weekly for 20 weeks
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.